The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease

References

• Cottin V, Wollin L, Fischer A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28(151):180100.
   Web of Science ®Google Scholar
• Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017;4(1):e000212.
   PubMed Web of Science ®Google Scholar
• Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57.
   PubMedGoogle Scholar
• Wells AU, Brown KK, Flaherty KR, et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51(5):1800692.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–253.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–1087.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials. Respir Med. 2016;113:74–79.
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718–1727.
   PubMed Web of Science ®Google Scholar
• Behr J, Neuser P, Prasse A, et al. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulm Med. 2017;17(1):122.
   PubMedGoogle Scholar
• Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the lotuss trial. J Rheumatol. 2016;43(9):1672–1679.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Varone F, Bergna M, et al. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018;27(150):180074.
   PubMed Web of Science ®Google Scholar
• Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res. 2020;21(1):32.
   PubMed Web of Science ®Google Scholar
• Du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184(12):1382–1389.
   PubMed Web of Science ®Google Scholar
• Paterniti MO, Bi Y, Rekic D, et al. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2017;14(9):1395–1402.
   PubMed Web of Science ®Google Scholar
• Khanna D, Mittoo S, Aggarwal R, et al. Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - report from OMERACT CTD-ILD working group. J Rheumatol. 2015;42(11):2168–2171.
   PubMed Web of Science ®Google Scholar
• Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147–157.
   PubMed Web of Science ®Google Scholar
• Akira M, Inoue Y, Kitaichi M, et al. Usual interstitial pneumonia and nonspecific interstitial pneumonia with and without concurrent emphysema: thin-section CT findings. Radiology. 2009;251(1):271–279.
   PubMed Web of Science ®Google Scholar
• Chung JH, Montner SM, Adegunsoye A, et al. CT findings, radiologic-pathologic correlation, and imaging predictors of survival for patients with interstitial pneumonia with autoimmune features. Am J Roentgenol. 2017;208(6):1229–1236.
   PubMed Web of Science ®Google Scholar
• Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;172(4):488–493.
   PubMed Web of Science ®Google Scholar
• Lynch DA, Travis WD, Muller NL, et al. Idiopathic interstitial pneumonias: CT features. Radiology. 2005;236(1):10–21.
   PubMed Web of Science ®Google Scholar
• Hwang JH, Misumi S, Curran-Everett D, et al. Longitudinal follow-up of fibrosing interstitial pneumonia: relationship between physiologic testing, computed tomography changes, and survival rate. J Thorac Imaging. 2011;26(3):209–217.
   PubMed Web of Science ®Google Scholar
• Oda K, Ishimoto H, Yatera K, et al. High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15:10.
   PubMed Web of Science ®Google Scholar
• Yamauchi H, Bando M, Baba T, et al. Clinical course and changes in high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis without honeycombing. PLoS One. 2016;11(11):e0166168–e.
   PubMed Web of Science ®Google Scholar
• Robbie H, Daccord C, Chua F, et al. Evaluating disease severity in idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26(145):170051.
   PubMed Web of Science ®Google Scholar
• Walsh SLF, Devaraj A, Enghelmayer JI, et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180073.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003;58(2):143–148.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–1328.
   PubMed Web of Science ®Google Scholar
• Oldham JM, Adegunsoye A, Valenzi E, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016;47(6):1767–1775.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723–728.
   PubMed Web of Science ®Google Scholar
• Ohshimo S, Ishikawa N, Horimasu Y, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med. 2014;108(7):1031–1039.
   PubMed Web of Science ®Google Scholar
• Drakopanagiotakis F, Wujak L, Wygrecka M, et al. Biomarkers in idiopathic pulmonary fibrosis. Matrix Biol. 2018;68–69:404–421.
   PubMed Web of Science ®Google Scholar
• Alqalyoobi S, Adegunsoye A, Linderholm A, et al. Circulating plasma biomarkers of progressive interstitial lung disease. Am J Respir Crit Care Med. 2020;201(2):250–253.
   PubMed Web of Science ®Google Scholar
• Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(6):711–718.
   PubMed Web of Science ®Google Scholar
• Degryse AL, Lawson WE. Progress toward improving animal models for idiopathic pulmonary fibrosis. Am J Med Sci. 2011;341(6):444–449.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208(7):1339–1350.
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Toews GB, White ES, et al. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55(1):395–417.
   PubMedGoogle Scholar
• Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2015;24(135):102–114.
   PubMed Web of Science ®Google Scholar
• Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54:1900161.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. 2001;164(9):1722–1727.
   PubMed Web of Science ®Google Scholar
• Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016;48(6):1710–1720.
   PubMed Web of Science ®Google Scholar
• Ley B, Newton CA, Arnould I, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017;5(8):639–647.
   PubMed Web of Science ®Google Scholar
• Juge PA, Lee JS, Ebstein E, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379(23):2209–2219.
   PubMed Web of Science ®Google Scholar
• Herzog EL, Mathur A, Tager AM, et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol (Hoboken). 2014;66(8):1967–1978.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2)e3–19.
   PubMed Web of Science ®Google Scholar
• Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186(1):88–95.
   PubMed Web of Science ®Google Scholar
• Raghu G, Anstrom KJ, King TE, Jr., et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977.
   PubMed Web of Science ®Google Scholar
• Park SH, Saleh D, Giaid A, et al. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med. 1997;156(2 Pt 1):600–608.
   PubMed Web of Science ®Google Scholar
• Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158(9):641–649.
   PubMed Web of Science ®Google Scholar
• Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013;42(6):1622–1632.
   PubMed Web of Science ®Google Scholar
• Kolb M, Raghu G, Wells AU, et al. Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2018;379(18):1722–1731.
   PubMed Web of Science ®Google Scholar
• Macias-Barragan J, Sandoval-Rodriguez A, Navarro-Partida J, et al. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010;3:16.
   PubMedGoogle Scholar
• Roth GJ, Binder R, Colbatzky F, et al. Nintedanib: from discovery to the clinic. J Med Chem. 2015;58(3):1053–1063.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Kreuter M, Selman M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018;73(6):581.
   PubMed Web of Science ®Google Scholar
• Nakazato H, Oku H, Yamane S, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002;446(1–3):177–185.
   PubMed Web of Science ®Google Scholar
• FDA approves first treatment for group of progressive interstitial lung diseases; 2020 [cited 2020 Mar 31]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-group-progressive-interstitial-lung-diseases
   Google Scholar
• Corte TJ, Ellis R, Renzoni EA, et al. Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia. Sarcoidosis, Vasculitis, Diffuse Lung Dis. 2009;26(2):132–138.
   PubMed Web of Science ®Google Scholar
• Kinder BW, Shariat C, Collard HR, et al. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung. 2010;188(2):143–149.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–719.
   PubMed Web of Science ®Google Scholar
• Wells A, Flaherty K, Brown K, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453–460.
   Web of Science ®Google Scholar
• Goldberg HJ. Understanding progressive fibrosing interstitial lung disease through therapeutic trials. N Engl J Med. 2019;381(18):1775–1777.
   PubMed Web of Science ®Google Scholar
• Guenther A, Prasse A, Kreuter M, et al. Late breaking abstract - exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF). Eur Respir J. 2019;54(suppl63):RCT1879.
   Google Scholar
• Skolnik K, Ryerson CJ. Unclassifiable interstitial lung disease: A review. Respirology. 2016;21(1):51–56.
   PubMed Web of Science ®Google Scholar
• Guler SA, Ellison K, Algamdi M, et al. Heterogeneity in unclassifiable interstitial lung disease. A systematic review and meta-analysis. Ann Am Thorac Soc. 2018;15(7):854–863.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013;42(3):750–757.
   PubMed Web of Science ®Google Scholar
• Peikert T, Daniels CE, Beebe TJ, et al. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med. 2008;102(9):1342–1348.
   PubMed Web of Science ®Google Scholar
• Jo H, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian idiopathic pulmonary fibrosis registry. Eur Respir J. 2017;49:1601592.
   PubMed Web of Science ®Google Scholar
• Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015–2024.
   PubMed Web of Science ®Google Scholar
• Salisbury ML, Gu T, Murray S, et al. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest. 2019;155(4):699–711.
   PubMed Web of Science ®Google Scholar
• Lee SM, Seo JB, Oh SY, et al. Prediction of survival by texture-based automated quantitative assessment of regional disease patterns on CT in idiopathic pulmonary fibrosis. Eur Radiol. 2018;28(3):1293–1300.
   PubMed Web of Science ®Google Scholar
• Jacob J, Hirani N, van Moorsel CHM, et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J. 2019;53(1):1800869.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5(4):e93.
   PubMed Web of Science ®Google Scholar
• Kennedy B, Branagan P, Moloney F, et al. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis. Sarcoidosis, Vasculitis, Diffuse Lung Dis. 2015;32(3):228–236.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006;11(2):164–168.
   PubMed Web of Science ®Google Scholar
• Olson AL, Gifford AH, Inase N, et al. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018;27(150):180077.
   PubMed Web of Science ®Google Scholar